ESBLs: A Clear and Present Danger?
Rishi H‐P Dhillon,John Clark +1 more
TLDR
An overview of the current situation regarding ESBLs is given, with a focus on the epidemiology and management of such infections.Abstract:
Extended spectrum β-lactamases (ESBLs) are enzymes produced by a variety of Gram negative bacteria which confer an increased resistance to commonly used antibiotics. They are a worrying global public health issue as infections caused by such enzyme-producing organisms are associated with a higher morbidity and mortality and greater fiscal burden. Coupled with increasing prevalence rates worldwide and an ever diminishing supply in the antibiotic armamentarium, these enzymes represent a clear and present danger to public health. This article aims to give an overview of the current situation regarding ESBLs, with a focus on the epidemiology and management of such infections.read more
Citations
More filters
Journal ArticleDOI
Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data
Thomas P. Van Boeckel,Sumanth Gandra,Ashvin Ashok,Quentin Caudron,Bryan T. Grenfell,Bryan T. Grenfell,Simon A. Levin,Ramanan Laxminarayan,Ramanan Laxminarayan,Ramanan Laxminarayan +9 more
TL;DR: To prevent a striking rise in resistance in low-income and middle-income countries with large populations and to preserve antibiotic efficacy worldwide, programmes that promote rational use through coordinated efforts by the international community should be a priority.
Journal ArticleDOI
10 × '20 Progress—Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
Helen W. Boucher,George H. Talbot,Daniel K. Benjamin,Daniel K. Benjamin,John S. Bradley,John S. Bradley,Robert Guidos,Ronald N. Jones,Barbara E. Murray,Robert A. Bonomo,David N. Gilbert,David N. Gilbert +11 more
TL;DR: This survey demonstrates some progress in development of new antibacterial drugs that target infections caused by resistant GNB, but progress remains alarmingly elusive.
Journal ArticleDOI
Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management
Keith S. Kaye,Jason M. Pogue +1 more
TL;DR: In treating resistant gram‐negative infections, a review of surveillance data and hospital‐specific antibiograms, including resistance patterns within local institutions, and consideration of patient characteristics are helpful in guiding the choice of empiric therapy.
Journal ArticleDOI
Survival and Evolution of a Large Multidrug Resistance Plasmid in New Clinical Bacterial Hosts
TL;DR: It is suggested that insertion sequences play an important role in plasmid evolution by maintaining the plasticity necessary to alleviate plasmids–host constrains and the observed evolutionary strategy consistently followed by all evolved E. coli lineages exposes a trade-off between horizontal and vertical transmission.
Journal ArticleDOI
Synergistic and Additive Effect of Oregano Essential Oil and Biological Silver Nanoparticles against Multidrug-Resistant Bacterial Strains.
Sara Scandorieiro,Larissa Ciappina De Camargo,César Armando Contreras Lancheros,Sueli Fumie Yamada-Ogatta,Celso Vataru Nakamura,Admilton Gonçalves de Oliveira,Célia Guadalupe Tardeli de Jesus Andrade,Nelson Durán,Gerson Nakazato,Renata Katsuko Takayama Kobayashi +9 more
TL;DR: This study describes for the first time the synergistic and additive interaction between OEO and bio-AgNP produced by F. oxysporum against multidrug-resistant bacteria, such as MRSA, and β-lactamase- and carbapenemase-producing Escherichia coli and Acinetobacter baumannii strains.
References
More filters
Journal ArticleDOI
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Helen W. Boucher,George H. Talbot,John S. Bradley,John S. Bradley,John E. Edwards,John E. Edwards,David N. Gilbert,Louis B. Rice,Louis B. Rice,Michael Scheld,Brad Spellberg,Brad Spellberg,John G. Bartlett +12 more
TL;DR: An update on potentially effective antibacterial drugs in the late-stage development pipeline is provided, in the hope of encouraging collaboration between industry, academia, the National Institutes of Health, the Food and Drug Administration, and the Centers for Disease Control and Prevention work productively together.
Journal ArticleDOI
Antimicrobial-Resistant Pathogens Associated with Healthcare- Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010
Dawn M. Sievert,Philip Ricks,Jonathan R. Edwards,Amy Schneider,Jean B. Patel,Arjun Srinivasan,Alex Kallen,Brandi Limbago,Scott K. Fridkin +8 more
TL;DR: The frequency of selected antimicrobial resistance patterns among pathogens causing device-associated and procedure-associated healthcare-associated infections reported by hospitals in the National Healthcare Safety Network (NHSN) is described.
Journal ArticleDOI
Extended-spectrum beta-lactamases: a clinical update.
TL;DR: Extended-spectrum β-lactamases represent an impressive example of the ability of gram-negative bacteria to develop new antibiotic resistance mechanisms in the face of the introduction of new antimicrobial agents.
Journal ArticleDOI
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study
Karthikeyan Kumarasamy,Mark Toleman,Timothy R. Walsh,Jay Bagaria,Fafhana Butt,Ravikumar Balakrishnan,Uma Chaudhary,Michel Doumith,Christian G. Giske,Seema Irfan,Padma Krishnan,Anil Kumar,Sunil Maharjan,Shazad Mushtaq,Tabassum Noorie,David L. Paterson,A. Pearson,Claire Perry,Rachel Pike,Bhargavi Rao,Ujjwayini Ray,Jayanta B. Sarma,Madhu Sharma,Elizabeth Sheridan,M A Thirunarayan,Jane F. Turton,Supriya Upadhyay,Marina Warner,William Welfare,David M. Livermore,Neil Woodford +30 more
TL;DR: The prevalence of NDM-1, in multidrug-resistant Enterobacteriaceae in India, Pakistan, and the UK is investigated, and co-ordinated international surveillance is needed.
Related Papers (5)
Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A-P Magiorakos,Arjun Srinivasan,R B Carey,Yehuda Carmeli,Matthew E. Falagas,Matthew E. Falagas,Christian G. Giske,Stéphan Juergen Harbarth,Janet F. Hindler,Gunnar Kahlmeter,Barbro Olsson-Liljequist,David L. Paterson,Louis B. Rice,John Stelling,Marc Struelens,Alkiviadis Vatopoulos,J T Weber,Dominique L Monnet +17 more